Home' Australian Pharmacist : Australian Pharmacist June 2016 Contents Australian Pharmacist June 2016 I ©Pharmaceutical Society of Australia Ltd.
A no surprises pre-election
BY BRAD WATTS
The Turnbull Government delivered a ‘no surprises’ 2015 health Budget, mainly
because many of the significant budget measures had already been leaked.
The focus quickly moved on to the
announcement of a double dissolution
election scheduled for 2 July.
Primary healthcare reforms being
progressed as part of the Budget could
provide opportunities for greater
involvement of pharmacists.
PSA questioned whether the funding
allocated to some primary healthcare
programs would be enough to have a
real impact on consumer health.
National Vice President Michelle
Lynch said pharmacists welcomed the
allocation of $21.3 million over four
years to trial the Health Care Homes
model, recommended by the Primary
Healthcare Advisory Group.
The trial will support primary care
providers to deliver coordinated
care, management and support to
approximately 65,000 people with chronic
and complex conditions in Australia.
‘PSA questions if $100 (approx.)
per patient per annum – or around
$35,000 per healthcare home –
is sufficient for patients with the most
chronic needs to access genuine
integrated care – which includes
having a pharmacist on the team,’
Ms Lynch said.
She said pharmacists welcomed the
tobacco excise increase that will provide a
major public health boost for Australians.
‘ The evidence-based changes to
tobacco excise will improve the health of
Australians by reducing their exposure
to tobacco products however this needs
to be combined with investment in
smoking cessation programs through
the highly-accessible community
PSA also welcomed the proposed
redesign of the Practice Incentives
Program (PIP) which, it said, would
provide increased flexibility for general
practice through Quality Improvement
‘We look forward to contributing to
the design of these reforms based
on best practice examples before the
implementation of new arrangements
in May 2017, as part of our ongoing
advocacy, supporting a model for
pharmacists in General Practice,’
Ms Lynch said.
Ms Lynch said small business – which
included community pharmacy – would
also benefit from personal income
tax and small business depreciation
From 1 July 2016, small businesses with
annual turnover less than $10 million
will have a company tax rate of 27.5 per
cent. Small businesses will also be able
access instant write-offs for equipment
purchased up to $20,000 for a business
with a turnover less than $10 million.
The Government also announced it
would refocus after-hours primary
care funding, but only funded GPs to
be involved in these services, through
practice incentives. This ignored other
key primary health professionals such
as pharmacists who are an integral part
of after-hours care, as acknowledged
by the recent Victorian Government
budget announcement to support
The positives in the Budget included
the previously announced review of
MBS services. It was revealed at Budget
lockup that of the current 5,700 services
covered by the MBS, only 3% had
ever been assessed for effectiveness.
PSA advocates for evidence-based
medicine and this review is a strong step
in that direction for the MBS which could
see substantial savings. The PSA believes
that this could create opportunities
for investment in evidence-based
The announcement of a Primary Health
Care Advisory Group was welcome and
PSA would expect to see pharmacists as
integral members of this group.
Another potential positive for
consumers and the health system is
the invigoration of electronic health
records. The Government expects
to save $A2.5 billion a year through
the $485 million rescue package for
the eHealth record initiative which
will now be an opt-in rather than an
The opt-in approach addresses one of
the issues raised in the Government’s
review of eHealth records. Whilst the
Government confirmed that some of
the funding will go toward education
for health practitioners, only GPs will
be incentivised to participate in the
scheme. The Government’s review
of eHealth records identifies that the
majority of savings to be realised
through this measure is through more
appropriate medication management
– s o participation of pharmacists in the
development of this budget measure
will be critical.
MAKE THE SWITCH
References: 1. Merry, A. F., Gibbs, R. D., Edwards, J., Ting, G. S., Frampton, C., Davies, E. and Anderson, B. J. (2010). “Combined acetaminophen and ibuprofen for pain relief after oral surgery in adults: a randomized controlled trial” British Journal of
Anaesthesia 104(1): 80-88. Result achieved in a trial of post-operative pain relief after removal of 1–4 wisdom teeth using Maxigesic® compared with Paracetamol 4000mg or Ibuprofen 1200mg alone per day in four divided doses.
Maxigesic® film coated tablets (Paracetamol 500mg and Ibuprofen 150mg; 10s, 16s and 30s) are a Pharmacist Only (S3) Medicine for the temporary relief of pain and reduction of fever. The usual dosage for Adults and Children over 12 years is 1-2 tablets
taken every 6 hours with a full glass of water, as required, up to a maximum of 8 tablets in 24 hours. Patients should not take more than 8 tablets in a 24 hour period. Incorrect use can be harmful. Do not use in children under 12 years or if patients have
kidney disease. Do not use if patients have asthma or a stomach ulcer. Do not combine with any other Paracetamol or Ibuprofen containing medicines. Patent No. 2005260243.
AFT Pharmaceuticals Pty Ltd | Sydney | ABN 29105636413 | WEBSITE www.aftpharm.com
FREE PHONE 1800 2387 4276 | FREE FAX 1800 041 026 | EMAIL email@example.com
DOUBLE ACTION PAIN RELIEF WITHOUT CODEINE
}MAXIGESIC® DELIVERS MORE
MAXIGESIC® delivers 2.7 times more Paracetamol
and 2 times more Ibuprofen than Nuromol®** at
maximum recommended daily dosage, if required.*
Clinically proven to reduce pain levels by at least 32%
more than a full daily OTC dose of either Paracetamol
or Ibuprofen alone1.
}SIMPLE, FLEXIBLE DOSAGE REGIMEN
1–2 tablets up to 4 times per day,
if required, offers flexibility and control
in managing daily pain
MAXIGESIC® is the only combination analgesic that delivers
the maximum recommended daily OTC dose of Paracetamol
4000mg and Ibuprofen 1200mg, if required.*
HARTLEY ATKINSON, Pharmacologist and Inventor of MAXIGESIC®
* 2 tablets of MAXIGESIC® taken every 6 hours over a 24 hour period
** Nuromol® is a registered trademark of Reckitt Benckiser Group PLC
Please review the full Product Information before
recommending, available at www.maxigesic.com.au
Brad Watts is the Executive director of
communications for PSA.
Links Archive Australian Pharmacist May 2016 Australian Pharmacist July 2016 Navigation Previous Page Next Page